- Home
- About SRT
- Strategy
- Team
- Bruce Thompson
- Carl Segvich
- Charles Columbus
- Christopher Mann
- David Clissold
- Derek Holmes
- Dhesh Govender
- Dr. Andrew Wilber
- Dr. Aurelio Maggio
- Dr. Chris Ballas
- Dr. Franco Locatelli
- Dr. Frank Park
- Dr. Gesualdo Loreto
- Dr. Isabelle Riviere
- Dr. Jeffrey S. Isenberg
- Bruce Thompson
- Carl Segvich
- Charles Columbus
- Christopher Mann
- David Clissold
- Derek Holmes
- Dhesh Govender
- Dr. Andrew Wilber
- Dr. Aurelio Maggio
- Dr. Chris Ballas
- Dr. Franco Locatelli
- Dr. Frank Park
- Dr. Gesualdo Loreto
- Dr. Isabelle Riviere
- Dr. Jeffrey S. Isenberg
- Dr. John Tisdale
- Dr. Julie Makani
- Dr. Lucio Luzzatto
- Dr. Maria Domenica (Nica) Cappellini
- Dr. Michel Sadelain
- Dr. Robyn Feldman
- Enrico Coluzzi
- Giancarlo Girondi
- Jason Feldman
- Joseph Feldman
- Ken Sussmane
- Kevin Dever
- Kevin Murphy
- Lenore Horton
- Megan Euker
- Michael Schaub
- Paritosh Ladhani
- Pat Girondi
- Press & Publications
- RICO Lawsuit against pharma bosses
- TrialSite News: LA Times Piece Glosses Over Gritty Realities Beta Thalassemia Gene Therapy: Bluebird Bio vs. San Rocco Therapeutics
- Trialsite News: FDA Approves First Gene Therapy for Beta-Thalassemia Patients Who Require Regular Red Blood Cell Transfusions: $2.8m Cost
- Business Wire: San Rocco Therapeutics, LLC (“SRT”) Pushes Clinical Trial for a Curative Treatment for Beta-Thalassemia and Sickle Cell Disease
- Molecular Therapy: Globin vector regulatory elements are active in early hematopoietic progenitor cells: Sadelain et al on importance of insulators
- Biospace: Errant Escalates Complaints to Lawsuit Over bluebird bio’s Gene Therapy
- TrialSite News: Errant Gene Therapeutics, LLC (“EGT”), Files PatentInfringement Complaint Against Defendant BluebirdBio
- Molecular Therapy: “Lentiviral vector ALS20 yields high hemoglobin levels with low genomic integrations for treatment of beta-globinopathies”
- TrialSite News: “The Family Man Gets His Day in Court: EGT Vs. Bluebird Bio”
- Gene Therapy With The Lentiviral Vector Tns9.3.55 Produces Long-Term Improvement In Severe ß-Thalassemia
- Errant Gene Therapeutics (EGT) Wins Major Victory in New York Appeals Court
- PubMed: Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects
- Federal Grant Awarded To Chicago BioMed Firm To Advance Research on Thalassemia
- Patrick Girondi Responds to New York Times on the Corrupt Expenses of Gene Therapy
- TrialSite News: FDA Rejects Petition for Review of Gene Therapy Product for Safety Concerns Involving Vulnerable Patient Population
- EIN Presswire: Megan Euker, Acclaimed Project Manager, Wins Coveted Award SAN ROCCO THERAPEUTICS (SRT) Announces
- Makani and Luzzatto, Of mice and men: From hematopoiesis in mouse models to curative gene therapy forsickle cell disease, Cell (2022)
- MSKCC: Clinical Trial for Beta-Thalassemia Brings Important Insights for Treating Blood Disorders with Stem Cell Gene Therapy
- Fierce Pharma:Tiny biotech Errant sues Bluebird for patent infringement in developing gene therapy LentiGlobin
- Bloomberg Law News: Bluebird Is Sued Over Patents Related to Blood-Disease Drug
- TrialSite News: “UK’s NICE Rejects bluebird bio: Questions Value Price Tag & Nominal Clinical Evidence While Sponsor Shocked”
- Bloomberg: “Former Chicago trader battles medical science giants over gene therapy deal”
- TrialSite News: “Errant Gene Therapeutics’ Gene Therapy Vector Shows Promise for Sickle Cell Disease and Thalassemia Patients”
- TrialSite News: “Pharma Drama: bluebird bio, Inc. Directors Accused of “Grossly Excessive” Compensation While Separate Errant Gene Therapeutics Lawsuit Heads for Trial
- Streetwise Father Takes On Sloan Kettering to Save His Sick Son
- Letters to Nature: “Therapeutic haemoglobin syntheseis in B-thalassaemic mice expressing lentivirus-encoded human B-globin”
- Rare & Orphan Diseases
- Science & Technology
- Product Pipeline
- Contact
